Today, the EVP & CFO of Spectrum Pharmaceuticals (SPPI), Kurt Gustafson, sold shares of SPPI for $32.19K.
This is Gustafson’s first transaction since reporting a Buy transaction on HALO back in August 2011 In addition to Kurt Gustafson, one other SPPI executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Spectrum Pharmaceuticals has an average volume of 640K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $25.25, reflecting a 136.9% upside.
In the last 30 days, insiders have sold $32.19K worth of SPPI shares and purchased $27.78K worth of SPPI shares. The insider sentiment on Spectrum Pharmaceuticals has been positive according to 69 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
